RXi Pharmaceuticals Corp  

(Public, NASDAQ:RXII)   Watch this stock  
Find more results for RXII
1.14
-0.07 (-5.79%)
Jan 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.13 - 1.24
52 week 0.91 - 6.84
Open 1.24
Vol / Avg. 0.00/302,851.00
Mkt cap 25.57M
P/E     -
Div/yield     -
EPS -1.03
Shares 21.13M
Beta     -
Inst. own 9%
Feb 9, 2015
RXi Pharmaceuticals Corp at Biotechnology Industry Organization CEO & Investor Conference - 9:00AM EST - Add to calendar
Jan 12, 2015
RXi Pharmaceuticals Corp at EBD Biotech Showcase
Nov 13, 2014
Q3 2014 Rxi Pharmaceuticals Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -13787.50% -5244.36%
Operating margin -13806.25% -5250.38%
EBITD margin - -5225.56%
Return on average assets -75.46% -203.85%
Return on average equity -457.90% -
Employees 12 -
CDP Score - -

Address

257 Simarano Dr Ste 101
MARLBOROUGH, MA 01752-3070
United States - Map
+1-508-7673861 (Phone)
+1-508-7673862 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

RXi Pharmaceuticals Corporation (RXi) is a development-stage company. The Company is a biotechnology company focused on discovering, developing and commercializing therapies addressing medical needs using RNA interference (RNAi)-targeted technologies. As of July 12, 2012, RXi was focusing its internal therapeutic development efforts in fibrosis. RXI-109 is its RNAi product candidate, which is a dermal anti-scarring therapy that targets connective tissue growth factor (CTGF). The Company�s therapeutic platform consists of two main components: RNAi Compounds (rxRNA) and Advanced Delivery Technologies. RNAi compounds include rxRNAori, rxRNAsolo and sd-rxRNA, or self-delivering RNA. On April 26, 2012, it completed the spin-off transaction from Galena Biopharma, Inc. (Galena).

Officers and directors

Robert J. Bitterman Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Geert Cauwenbergh Ph.D. President, Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Pamela J. Pavco Ph.D. Chief Development Officer
Age: 57
Bio & Compensation  - Reuters
Keith L. Brownlie CPA Independent Director
Age: 61
Bio & Compensation  - Reuters
H. Paul Dorman Independent Director
Age: 77
Bio & Compensation  - Reuters
Curtis A. Lockshin Ph.D. Independent Director
Age: 53
Bio & Compensation  - Reuters